Medtronic plc MDT
Composite 57/100; the shares have moved about 27% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 46/100 — a slight mark against it.
Income ranks 73/100 — a moderate point in its favour. Balance-sheet strength ranks 72/100 — a moderate point in its favour. Quality ranks 57/100 — a slight point in its favour.
Valuation ranks 46/100 — a slight mark against it.
What the company does Medtronic plc (MDT) designs and markets device-based medical therapies across three segments: Cardiovascular (pacemakers, valves, stents), Neuroscience (spinal cord stimulators, drug pumps), and Medical Surgical (ECMO, ablation tools). It serves global healthcare systems with implantable, interventional, and monitoring solutions.
Key financials Medtronic posts 65.3% gross margin and 13.2% net margin on $109.30B market cap. Revenue grew 9.9% and EPS 18.3% recently. ROE is 9.8%, ROA 4.9%, and ROCE 8.4%. Debt/equity is 0.58 with interest coverage of 9.58x and current ratio 2.13.
Stock health Strength pillar is high at 70.7, but momentum and growth sit near the median at 48.6 and 51.8. Dividend yield is 3.2% with a 51.5% payout. Piotroski F-Score is 7/9 and Altman Z is 2.82, indicating moderate financial health.
Price vs fair value MDT trades at a discount of 8.60% versus the analyst mean target of 98.44 (Simply Wall St.). - Recent CE Mark win cited as a catalyst for upside (Simply Wall St.). - Upgrades noted alongside valuation questions (Simply Wall St.). - Peer comparisons highlight growth vs turnaround trade-offs (Insider Monkey).
Looking forward Forward P/E of 14.33 and PEG of 0.24 suggest modest earnings multiples relative to growth. Analysts flag valuation sensitivity after product approvals and peer performance. Execution on neuroscience and cardiovascular pipelines remains key to sustaining momentum.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.